Stay updated with breaking news from John Throup. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals
Phase 1a clinical trial of JNT-517 in healthy volunteers approaching completionBOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, will present preclinical data for its lead...
/PRNewswire/ -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for highly validated,...
Global D-Phenylalanine Market Size Estimated To Reach $1,538.7 Million by 2027